| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
Ferroptosis pathway (lipid peroxidation, iron metabolism). Ferroptosis-IN-6 targets key enzymes or pathways involved in ferroptosis, including lipid peroxidation and iron-dependent cell death. It inhibits STY-BODIPY oxidation, indicating inhibition of lipid peroxidation. The exact molecular target is not specified in the available literature.
|
|---|---|
| ln Vitro |
Ferroptosis-IN-6 is a potent inhibitor of ferroptosis with an EC50 of 25.5 nM. It significantly inhibits RSL3-induced cell death. It inhibits STY-BODIPY oxidation, demonstrating inhibition of lipid peroxidation. It protects cells from ferroptosis induced by ferroptosis inducers.
|
| ln Vivo |
Ferroptosis-IN-6 significantly inhibits RSL3-induced cell death in vivo. It can be used for research on ischemia-reperfusion injury. In vivo, ferroptosis inhibitors have potential therapeutic applications in ischemia-reperfusion injury, neurodegenerative diseases, and other conditions involving ferroptosis.
|
| Enzyme Assay |
In vitro ferroptosis inhibition assays are performed using cells treated with ferroptosis inducers (e.g., RSL3, erastin) and varying concentrations of Ferroptosis-IN-6. Cell viability is measured using standard assays (MTT, CCK-8). Lipid peroxidation is measured using fluorescent probes such as C11-BODIPY 581/591. EC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cells (e.g., fibroblasts, cancer cells, or primary cells) are treated with Ferroptosis-IN-6 prior to or concurrently with ferroptosis induction by RSL3 or erastin. Cell viability is measured by standard assays. Lipid peroxidation is assessed by flow cytometry or fluorescence microscopy using C11-BODIPY 581/591. Ferroptosis-IN-6 shows EC50 of 25.5 nM.
|
| Animal Protocol |
Animal models of ischemia-reperfusion injury (e.g., renal or cerebral ischemia-reperfusion) are used to assess Ferroptosis-IN-6's in vivo efficacy. Ferroptosis-IN-6 is administered via intraperitoneal or intravenous routes. Tissue injury, lipid peroxidation markers, and functional outcomes are assessed to evaluate protection against ferroptosis-mediated injury.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Ferroptosis-IN-6 have not been extensively characterized. Molecular formula: C15H17NO. It is a small-molecule inhibitor with potential for oral or parenteral administration. Detailed PK data (Cmax, Tmax, AUC, t1/2) are not available in the literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for Ferroptosis-IN-6 are not available. As a ferroptosis inhibitor, its toxicity profile is unknown. It is not intended for human use. Standard laboratory safety practices should be followed when handling the compound.
|
| References | |
| Additional Infomation |
Ferroptosis-IN-6 is a research-grade potent ferroptosis inhibitor. CAS: 1517780-59-4. EC50: 25.5 nM. It significantly inhibits RSL3-induced cell death and STY-BODIPY oxidation. It can be used for research on ischemia-reperfusion injury. Molecular formula: C15H17NO. For research use only.
|
| Exact Mass |
227.131
|
|---|---|
| CAS # |
1517780-59-4
|
| PubChem CID |
82680089
|
| Appearance |
Brown to dark brown solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
223
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC=C(C=C1)CNC2=CC=CC(=C2O)C
|
| InChi Key |
DPIILYUBOSNTOP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H17NO/c1-11-6-8-13(9-7-11)10-16-14-5-3-4-12(2)15(14)17/h3-9,16-17H,10H2,1-2H3
|
| Chemical Name |
2-methyl-6-[(4-methylphenyl)methylamino]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Typically soluble in DMSO (e.g. 10 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
